Skip to content

DEVANTHINIC PHARMA

Active Risk: not assessed Private limited companyfounded 2014active for 11 yearsRue des Canadiens 24, 7180 SeneffeKBO/BCE: BE 0506.893.294 #3 company by total assets in Seneffe, Administrative and support services sector
DEVANTHINIC PHARMA
Follow ReportCompare

Overview

Lifetime

11 annual accounts with figures on one time axis
peak €1.4m (2024)
€1.3m▼ 5.5%
peak €1.8m (2022)
€888,590▼ 9.6%
peak €7.7m (2025)
€7.7m▲ 13.0%
€8.7m▼ 9.7%
peak 8.4 FTE (2025)
8.4 FTE▲ 25.4%
Board1 name since 2014
1 directorANDRÉ Anne, Léa, Marie
Documentsfilings and deeds
27-08-202627 days late
2025abbreviated format
Staff from 6.7 FTE to 8.4 FTEEquity from €6.8m to €7.7mInvestments €44,601

Key points

from the 2025 annual accounts

Equity

€7.7m ▲ 13.0%

DEVANTHINIC PHARMA has made a profit in every financial year since 2015.

Investments

€33,902 10.9 × depreciation
2021202220232025

Green is investment, beige is depreciation. Machinery stands 303.3% higher than in 2024.

Staff

14 employees on 31-12-2025
202021312022322024822025

In 2025, 8 people joined and 2 left.

Filings

11 annual accounts since 2015
AprilJune31 JulyOctober201520202025

Nine of the last ten came late. The 2019 accounts came latest: 87 days after the end of the period.

Group

12 companies controlled

Heads a group.

Position in the sector

€888,590

Higher net result than 95% of companies in office administrative support. Sector median €20,911 · 2,833 companies.

Holding: outside the score modelBankruptcy probability: sector outside the model

Checked score

Outside the general model
Holding: general score not applicable
The company has a registered holding activity. Financial fixed assets make up more than half of its assets. The general model for operating companies does not fit such a balance sheet, so there is no score and no financial strength.

Bankruptcy probability within 12 months

The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

1 signal.
raises risk
raises risk · 2025 accounts filed 27 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-08-2026, 27 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filings
Deviation from the deadline
2025
27 days late
2024
29 days late
2023
26 days late
2022
on the day
2021
26 days late
2020
30 days late
2019
87 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 32 days after the deadline. In the sector (NACE 82), the median for financial year 2024 was 7 days before the deadline, and 35% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 27 August (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Board and ownership

AA
ANDRÉ Anne, Léa, Marie
Director, since 18-12-2014

Shares in 12 companies, including MARIEC.C-PHARMA and PHAMALIMO

Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0506893294
Appointment: ANDRÉ Anne Léa (statutory director) Gazette deed
Merger: DEVANTHINIC PHARMA takes over PHARMA-ZI Cancellation of 100 shares · The company holds all the shares of PHARMA-ZI · General meeting of 28-06-2018 · Gazette deed
Merger proposal: DEVANTHINIC PHARMA takes over PHARMA-ZI The company holds all the shares of PHARMA-ZI · Gazette deed
All 23 events

Comparable companies

same main activity, similar in size and age
Company
DEVANTHINIC PHARMA Seneffe €16.8m €1.3m 46.0% 8.4
DE DEURWAERDER-van PUTTEN Gistel €26.0m €1.2m 88.4% 9.2
IM INVEST Asse €19.0m €1.0m 72.8% 6.5
DYNERGY Beveren-Kruibeke-Zwijndrecht €23.4m €1.6m 93.0% 6.9
Advanced Engineering Center Charleroi €11.8m €0.8m 46.9% 6.5
STEENBERG Grimbergen €25.4m €1.3m 56.2% 6
LUMET HOLDING Beveren-Kruibeke-Zwijndrecht €16.3m €1.2m 12.7% 5.9

These companies have the same main activity as DEVANTHINIC PHARMA: other business support services (NACE 82990). They are comparable in size and age: total assets between €12m and €26m, founded between 2008 and 2019.

Official details

Source: KBO
Status
Active since 16-12-2014Normal situation
Registered office
13 active companies are registered at this address1 started in the 12 months before. Source: KBO register, as of 11 November 2026.
Activity
Other business support servicesNACE 82990and 1 other
Joint committees
313Pharmacies and pricing offices
121Cleaning
200Auxiliary committee for white-collar workers · annual accounts 2025
Establishment unit
2.237.633.3157180 Seneffe, since 18-12-2014
Financial year end
31 December
Peppol
Reachable since 29-12-2025
Company details

Annual accounts 2025

€1.3m▼ 5.5%
≈ €2.0mestimated
€888,590▼ 9.6%
€7.7m▲ 13.0%
€16.8m▲ 0.8%
Employeeson 31-12-2025
14▲ 75.0%
Filing
Filed on 27-08-2026
Financials

Companies linked to DEVANTHINIC PHARMA

Insights on DEVANTHINIC PHARMA

DEVANTHINIC PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €34,196 in 2015 to €1.3m in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2025

abbreviated format, filed on 27-08-2026, 27 days late
€7.7m
▲ 13.0%
€16.8m
▲ 0.8%
€888,590
▼ 9.6%
46.0%
▲ 5.0 percentage points
11.5%
▼ 2.9 percentage points
5.3%
▼ 0.6 percentage points

The turnover shown is an estimate from the gross margin.

Turnover ≈ €2.0m. Estimated: probably between €1.5m and €3.0m.

In the rankings #3 company by total assets in Seneffe, Administrative and support services sector#3 company by equity in Seneffe, Administrative and support services sector

Balance sheet

balance sheet total €16.8m on 31-12-2025
What the company ownsHow it is paid for

in €m

in euro

Position in the sector

Compare with sector

46.0%

Higher than 54% of 2,831 companies in 2025.

5.3%

Higher than 54% of 2,778 companies in 2025.

DEVANTHINIC PHARMA Middle half of the sector 80% of the sector Abbreviated accounts in office administrative support (NACE 82)

Net result: top quarter · Equity: top quarter · Balance sheet total: top quarter · Staff: top quarter

Staff

€51,369

Staff costs divided by the average number of full-time equivalents.

+6 people

people who joined people who left

In 2025, 8 people joined and 2 left.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend20252024202320222021202020192018201720162015
Balance sheet: assets
20/58 16.8m16.7m15.6m14.4m14.0m9.6m8.1m7.5m6.2m4.8m910,075
21/28 14.2m14.2m13.8m12.6m12.6m8.4m7.0m7.0m6.0m4.8m904,277
22/27 34,7023,90616,53710,4275,74214,65229,30543,95758,610--
23 517128433739-------
24 34,1853,77816,1049,6895,74214,65229,30543,95758,610--
28 14.2m14.2m13.8m12.6m12.6m8.4m7.0m7.0m5.9m4.8m904,277
29/58 2.6m2.5m1.8m1.8m1.4m1.2m1.1m547,724221,65090,0145,798
40/41 2.2m2.0m1.5m1.4m1.1m1.1m646,560501,050196,27285,6121,464
40 699,425464,126243,340222,314315,335276,966178,325118,846123,67570,8391,464
41 1.5m1.6m1.3m1.2m786,980774,626468,234382,20472,59714,773-
54/58 351,359462,442213,315401,330285,56899,497449,19646,21325,3664,4024,334
490/1 1,882-17,40624,2203,90892347446111--
Balance sheet: equity and liabilities
10/49 16.8m16.7m15.6m14.4m14.0m9.6m8.1m7.5m6.2m4.8m910,075
10/15 7.7m6.8m5.9m5.2m3.5m2.6m1.9m1.5m274,460207,372165,676
10/11 150,000150,000150,000150,000150,000150,000150,000150,000150,000150,000150,000
100 ------150,000150,000150,000150,000150,000
13 997,250534,150260,50050,00050,00050,00050,00050,00050,00050,00011,300
130/1 15,00015,00015,00015,00015,00015,000-----
130 ------15,00015,00015,00015,0001,300
1311 15,00015,00015,00015,00015,00015,000-----
132 947,250484,150210,500--------
133 35,00035,00035,00035,00035,00035,00035,00035,00035,00035,00010,000
14 6.6m6.2m5.5m5.0m3.3m2.4m1.7m1.3m74,4607,3724,376
16 390,110209,091---------
160/5 390,110209,091---------
164/5 390,110209,091---------
17/49 8.7m9.6m9.8m9.2m10.5m6.9m6.2m6.0m6.0m4.6m744,399
17 6.3m7.5m8.0m7.7m8.3m5.6m1.7m1.9m1.1m450,507484,221
170/4 6.3m7.5m8.0m7.7m8.3m5.6m1.7m1.9m1.1m450,507484,221
42/48 2.3m2.1m1.8m1.5m2.2m1.4m4.5m4.1m4.9m4.2m260,178
42 594,027585,500563,524526,532477,629257,613182,287179,612112,28133,71433,146
43 ----4,70210,031-----
430/8 ----4,70210,031-----
44 171,97299,60351,36644,21115,478--34,87533,7681158,260
440/4 171,97299,60351,36644,21115,478--34,87533,7681158,260
45 72,526110,38543,07181,473102,97230,21042,73444,23747,81019,68111,598
450/3 10,90375,08218,27055,28493,59526,15842,73444,23747,81019,68111,598
454/9 61,62435,30324,80126,1899,3774,052-----
47/48 1.5m1.3m1.1m847,3041.6m1.1m4.2m3.9m4.7m4.1m207,173
Income statement
9900 1.3m1.4m1.2m1.2m930,157517,767379,220325,924273,327109,31334,196
62 431,503367,160284,874233,80268,07019,634-----
630 3,1071,3894,3892,73914,91014,65214,652178,20214,652--
635/8 181,018209,091---------
640/8 101868-04----
66A -243---------
9901 703,739818,903943,306970,758847,177483,481364,563147,721258,675109,31334,196
75/76B 610,000675,000110,0001.2m350,000460,000270,0001.3m0042
75 610,000675,000110,0001.2m350,000460,000270,0001.3m0042
65/66B 266,940331,380227,909181,708206,327178,555174,443172,277157,06142,3608,975
65 266,940331,380227,909181,708206,327178,555174,443172,277157,06142,3608,975
9903 1.0m1.2m825,3972.0m990,850764,926460,1201.3m101,61466,95325,263
780 ---1,650-------
67/77 158,208179,345183,447204,797165,76173,47652,85734,37734,52625,2579,587
9904 888,590983,178641,9511.8m825,089691,451407,2631.3m67,08841,69615,676
689 463,100273,650210,500--------
9905 425,490709,528431,4511.8m825,089691,451407,2631.3m67,08841,69615,676
Appropriation of the result
9906 6.6m6.2m5.5m5.0m3.3m2.4m1.7m1.3m74,46046,07215,676
14P 6.2m5.5m5.0m3.3m2.4m------
691/2 ---------38,70011,300
6920 ---------13,7001,300
6921 ---------25,00010,000
Social balance sheet
9087 8.46.764.91.30.5-----
Hours worked1013 10,0249,3437,7047,8542,270840-----
Document PDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDF

The notes to these accounts have 13 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 27-08-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank

2025 annual accounts filed 27 days after the deadline. Filed on 27 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00479392.

Financial year Type Filed Reference Document
31-12-2025 abbreviated format 27-08-2026 2026-00479392 PDF
31-12-2024 full format 29-08-2025 2025-00443740 PDF
31-12-2023 full format 26-08-2024 2024-00378500 PDF
31-12-2022 full format 31-07-2023 2023-00314109 PDF
31-12-2021 full format 26-08-2022 2022-20336846 PDF
31-12-2020 full format 30-08-2021 2021-57000316 PDF
31-12-2019 micro format 26-10-2020 2020-63400033 PDF
31-12-2018 micro format 09-09-2019 2019-63900157 PDF
31-12-2017 micro format 02-08-2018 2018-43300430 PDF
31-12-2016 full format 08-08-2017 2017-42800595 PDF
31-12-2015 full format 17-08-2016 2016-43800444 PDF

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend20252024202320222021202020192018201720162015
44,601355,7311.2m7,4244.2m1.4m36,0021.2m1.3m3.9m904,277
-111,083249,127-188,016115,763186,071-349,699402,98320,84720,96468-
46.0%41.0%37.5%36.3%24.8%27.6%24.0%20.4%4.4%4.3%18.2%
11.5%14.4%11.0%33.6%23.8%26.2%20.9%82.2%24.4%20.1%9.5%
5.3%5.9%4.1%12.2%5.9%7.2%5.0%16.8%1.1%0.9%1.7%

EBIT margin: not included in this filing.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Social balance sheet

Item31-12-202531-12-202431-12-202331-12-202231-12-2021
Employees at the balance-sheet date148753
full-time52232
part-time96521
in full-time equivalents10.86.364.52.8
8.46.764.91.3
On a permanent contract148753
Joined83-32
Left22-10
Training hours-13--10

Source: social balance sheet in the 2021 to 2025 annual accounts

Investments

fixed assets acquired
Item20252024202320222021
Tangible fixed assets€33,902-€10,499€7,424€6,000
Financial fixed assets€10,699€355,731€1.2m-€4.2m
€3,107€1,389€4,389€2,739€14,910

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on DEVANTHINIC PHARMA

The operating result for 2025 is 14% lower than in 2024 and the lowest since 2020. It is the third fall in a row.

Debt's share of the balance-sheet total falls from 57.7% to 51.7%. Equity is higher and debt is lower.

Board & ownership

Board

1 director, last change in 2021
ANDRÉ Anne, Léa, Marie
Statutory director
since 18-12-2014 term without a fixed end
also on the board of 1 other company
listed in the 2025 annual accounts, filed on 27-08-2026
Signing authorityThe articles say who may bind the company, for example by signing a contract.
Each director alone
deed of 29-11-2021

Office holders in the KBO →

Mandates through the years

1 name, the dashed line is today
ANDRÉ Anne, Léa, Marie
Statutory director
Board
Mandates as a list
  • ANDRÉ Anne, Léa, Marie
    • Statutory director, from 18-12-2014 to date

See the board, name and registered office on a given date →

Control

See the annual accounts at the National Bank and the publications in the Belgian Official Gazette.

Capital

Contribution
€150,000
Source
2025 annual accounts

Articles of association

deed of 29-11-2021 (in French)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Board ruleThese rules set how the board is made up, meets and takes decisions.
“Organe d'administration, assemblée qui nomme fixe nombre, durée mandat et en cas de pluralité pouvoirs”
Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
“Moitié cédant moitié acquéreurs au prorata actions si plusieurs, cession d'actions”
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Last Thursday of May at 19:00

Network & group

Holdings

own 2025 accounts, the bar shows equity in euros
This companyDEVANTHINIC PHARMA12 holdings, 1 country 2025 accounts

Belgium 12 Year Equity Result

Source: list of holdings in its own 2025 accounts. Every holding stands with its own latest accounts.

Heads the group DEVANTHINIC PHARMA Group, risk and exposure
The LEI register names no parent.

At the same address

Rue des Canadiens 24, 7180 Seneffe · 12 other companies
PHARMACIE DE LA DRÊVE
registered office since 08-05-1981 · founded in 1981 · negative equity (2025) · group DEVANTHINIC PHARMA
 2.7 FTE (2025)
0421.582.883
PHARMACIE DE BASCOUP
registered office since 15-07-1996 · founded in 1996 · group DEVANTHINIC PHARMA
 3.8 FTE (2025)
0458.492.472
PHARMA-LOUVE
registered office since 13-12-2007 · founded in 2007 · group DEVANTHINIC PHARMA
 2.6 FTE (2025)
0894.160.549
PHARMACIE DE LA VILLE BASSE
registered office since 22-02-2005 · founded in 2005 · group DEVANTHINIC PHARMA
 4 FTE (2025)
0872.063.652
PHARMACIE SENEFFE CENTRE
registered office since 07-06-2002 · founded in 2002 · group DEVANTHINIC PHARMA
 4 FTE (2025)
0477.710.053
PHARMACIE ANNE ANDRE
registered office since 03-10-2002 · founded in 2002 · group DEVANTHINIC PHARMA
 5.1 FTE (2025)
0478.484.667
PHARMACIE DE LA GRAND RUE
registered office since 25-06-2012 · founded in 2012 · group DEVANTHINIC PHARMA
 2.9 FTE (2025)
0846.815.047
PHARMACIE DE BOIS-D'HAINE
registered office since 09-10-1987 · founded in 1987 · group DEVANTHINIC PHARMA
 2.3 FTE (2025)
0432.058.190
MARIEC.C-PHARMA
registered office since 22-12-2014 · founded in 2014 · group DEVANTHINIC PHARMA
 total assets €759,407 (2025)
0507.640.788
PHAMALIMO
registered office since 19-06-2012 · founded in 2012 · group DEVANTHINIC PHARMA · accounts filed late
 0.8 FTE (2024)
0846.675.386
and 2 more

Holdings and subsidiaries

12 holdings

Holdings 12

Share, source and own figures per holding (12)

Source for every holding own accounts 2025

  • MARIEC.C-PHARMAsubsidiary
    Equity €288,410 Loss of €127,351 in 2025 (loss of €28,201 in 2024) Checked score 66
    100%
  • PHAMALIMOsubsidiary
    Equity €2,614 Loss of €28,381 in 2024 (profit of €11,499 in 2023) Checked score 33
    100%
  • PHARMA-LOUVEsubsidiary
    Equity €1.1m Profit of €110,741 in 2025 (profit of €115,268 in 2024) Checked score 97
    100%
  • PHARMACIE ANNE ANDREsubsidiary
    Equity €510,301 Profit of €44,786 in 2025 (profit of €83,551 in 2024) Checked score 92
    100%
  • PHARMACIE BESONRIEUX CENTREsubsidiary
    Equity €8,035 Profit of €15,132 in 2025 (loss of €14,370 in 2024) Checked score 52
    Alsodeed 24-11-2023
    100%
  • PHARMACIE DE BASCOUPsubsidiary
    Equity €443,912 Profit of €141,586 in 2025 (profit of €214,074 in 2024) Checked score 88
    100%
  • PHARMACIE DE BOIS-D'HAINEsubsidiary
    Equity €393,589 Profit of €141,805 in 2025 (profit of €127,915 in 2024) Checked score 96
    100%
  • PHARMACIE DE LA DRÊVEsubsidiary
    Equity -€120,957 Loss of €44,195 in 2025 (loss of €64,782 in 2024) Checked score 53
    100%
  • PHARMACIE DE LA GRAND RUEsubsidiary
    Equity €659,956 Profit of €153,442 in 2025 (profit of €157,783 in 2024) Checked score 97
    100%
  • PHARMACIE DE LA VILLE BASSEsubsidiary
    Equity €532,133 Profit of €142,471 in 2025 (profit of €210,248 in 2024) Checked score 93
    100%
  • Pharmacie LOISEAUsubsidiary
    Equity €79,595 Loss of €750 in 2025 (loss of €2,585 in 2024) Checked score 87
    100%
  • PHARMACIE SENEFFE CENTREsubsidiary
    Equity €586,450 Profit of €215,723 in 2025 (profit of €258,689 in 2024) Checked score 95
    100%
Former holdings (1)
Holdings through the years 2015 to 2025
Holdings through the years
Name20152016201720182019202020212022202320242025
MARIEC.C-PHARMA 100%
PHAMALIMO 100%
PHARMA-LOUVE 100%10%100%
PHARMACIE ANNE ANDRE 100%
PHARMACIE BESONRIEUX CENTRE 100%
PHARMACIE DE BASCOUP 100%
PHARMACIE DE BOIS-D'HAINE 100%
PHARMACIE DE LA DRÊVE 100%
PHARMACIE DE LA GRAND RUE 100%
PHARMACIE DE LA VILLE BASSE 100%
Pharmacie LOISEAU 100%
PHARMACIE SENEFFE CENTRE 100%
PHARMACIE FAUCON 100%

Source: list of holdings in its own accounts

Board mandates elsewhere

7 board mandates
Board mandates of DEVANTHINIC PHARMADEVANTHINIC PHARMA sits on their board7
PHAMALIMO
Director
Founded in 2012 · 0.8 FTE (2024) · group DEVANTHINIC PHARMA · accounts filed late
PHARMA-LOUVE
Director
Founded in 2007 · 2.6 FTE (2025) · group DEVANTHINIC PHARMA
PHARMACIE DE LA VILLE BASSE
Director
Founded in 2005 · 4 FTE (2025) · group DEVANTHINIC PHARMA
PHARMACIE DE BOIS-D'HAINE
Director
Founded in 1987 · 2.3 FTE (2025) · group DEVANTHINIC PHARMA
MARIEC.C-PHARMA
Director
Founded in 2014 · total assets €759,407 (2025) · group DEVANTHINIC PHARMA
PHARMACIE BESONRIEUX CENTRE
Director
Founded in 2023 · 1.2 FTE (2025) · group DEVANTHINIC PHARMA
Show 1 more
Pharmacie LOISEAU
Director
Founded in 2002 · total assets €364,995 (2025) · group DEVANTHINIC PHARMA

Acquisitions and mergers

1 transaction
Took over:PHARMA-ZI
BE 0671.948.494Gazette deed of 27-07-2018 (2 deeds)

Connections & network

1 connected company
Depth

The connected companies are in the list below.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
DEVANTHINIC IMMO
via ANDRÉ Anne, Léa, Marie · Director · deed of 06-07-2026
Founded in 2026
→

Timeline

Timeline

23 events since 2014

Deadline for the 2026 accounts: 31-07-2027

2026
Annual accounts 2025 filed NBBabbreviated format · 27 days late
2025
Registered in the Peppol Directory Reachable for e-invoices through 0208:0506893294
Annual accounts 2024 filed PDFfull format · 29 days late
2024
Annual accounts 2023 filed PDFfull format · 26 days late
2023
Annual accounts 2022 filed PDFfull format · on the deadline day
2022
Highest result from 2015 to 2025 net €1.8m ▲113% The operating result of €970,758 and the net result of €1.8m are both a record.
Equity above €5m equity €5.2m ▲50.7% With a profit in every financial year since 2015, equity grows to €5.2m.
Annual accounts 2021 filed PDFfull format · 26 days late
2021
Appointment: ANDRÉ Anne Léa (statutory director)2 points ▸
  • Registered office clause, rue des Canadiens 24, 7180 Seneffe
  • Director appointment, ANDRÉ Anne Léa (statutory director)
  • The deed holds 8 more points.

Open the deed in the Belgian Official Gazette

Annual accounts 2020 filed PDFfull format · 30 days late
2020
Equity above €2m equity €2.6m ▲35.5% With a profit in every financial year since 2015, equity grows to €2.6m.
Annual accounts 2019 filed PDFmicro format · 87 days late
2019
Annual accounts 2018 filed PDFmicro format · 40 days late
2018
Equity above €1m equity €1.5m ▲461% With a profit in every financial year since 2015, equity grows to €1.5m.
Annual accounts 2017 filed PDFmicro format · 2 days late
Merger: DEVANTHINIC PHARMA takes over PHARMA-ZICancellation of 100 shares · The company holds all the shares of PHARMA-ZI · General meeting of 28-06-20184 points ▸
  • General meeting, 28-06-2018, mentioned twice in the deed
  • Accounting effect, 01-01-2018
  • The company holds all the shares of PHARMA-ZI
  • Power of attorney, Anne André (manager)
  • The deed holds 10 more points.

Open the deed in the Belgian Official Gazette

Merger proposal: DEVANTHINIC PHARMA takes over PHARMA-ZIThe company holds all the shares of PHARMA-ZI2 points ▸
  • Accounting effect, 01-01-2018
  • The company holds all the shares of PHARMA-ZI
  • The deed holds 4 more points.

Open the deed in the Belgian Official Gazette

2017
Permanent representative: De Vriese ThiblautBoard meeting of 30-09-20172 points ▸
  • Board meeting, 30-09-2017
  • Permanent representative, De Vriese Thiblaut, mentioned 4 times in the deed
  • The deed holds 1 more point.

Open the deed in the Belgian Official Gazette

Annual accounts 2016 filed PDFfull format · 8 days late
2016
Equity above €200,000 equity €207,372 ▲25.2% With a profit in every financial year since 2015, equity grows to €207,372.
Annual accounts 2015 filed PDFfull format · 17 days late
2014
First establishment Rue des Canadiens 24, Seneffe
Incorporation PDFpublished on 18-12-2014

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

On 16 December 2014, DEVANTHINIC PHARMA was incorporated.1 PHARMA-ZI was merged into the company in 2018.2 Total assets went from €7.5m in 2018 to €16.8m in 2025 and headcount from 0.5 full-time equivalents in 2020 to 8.4 in 2025.3

  1. 1KBO register
  2. 2Belgian Official Gazette, 27-07-2018
  3. 3National Bank, annual accounts 2018, 2020 and 2025

Company details

Identity

Enterprise number
0506.893.294
VAT number
BE 0506.893.294
Peppol ID
0208:0506893294
Other Peppol ID
9925:BE0506893294
LEI code
9845005496B8A81C7768 live in the LEI register
Legal form
Private limited company
Status
Active, normal situation
Founded
16-12-2014
Financial year
ends on 31 December
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Last Thursday of May at 19:00
deed of 29-11-2021 (in French)
Peppol
Reachable since 29-12-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
Name
DEVANTHINIC PHARMA in French
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 29-11-2021 (in French)

Activities

NACEBEL 2025
VAT activities
82990 Other business support services main activity
Social security (RSZ) activities
64210 Activities of holding companies main activity
Joint committees annual accounts 2025
JC 313 Pharmacies and pricing offices
JC 121 Cleaning
JC 200 Auxiliary committee for white-collar workers
Codes under NACEBEL 2008
VAT activities
82990 Other business support services main activity
Social security (RSZ) activities
64200 Holdings main activity
PurposeThe purpose describes the activities the company may carry out under its articles.
“Toutes opérations généralement quelconques,industrielles,commerciales,financières,mobilières ou immobilières se rapportant directement aux…”
4 activities
  1. Toutes opérations généralement quelconques,industrielles,commerciales,financières,mobilières ou immobilières se rapportant directement aux activités d'exploitation d'officines pharmaceutiques,homéopathiques et de bandagisteries,ainsi que la fabrication et la commercialisation de produits pharmaceutiques,homéopathiques et cosmétologiques
  2. Toutes activités et opérations d'une société d'investissement et de holding en ce compris:(1)l'investissement,la souscription,la prise ferme,le placement,la vente,l'achat et la négociation d'actions,parts et obligations,certificats,crédits,monnaies et autres valeurs mobilières émises par des entreprises belges ou étrangères qu'elles aient ou non la forme de sociétés commerciales,bureau d'administration,institutions ou associations et qu'elles aient ou non un statut juridique(semi-)public;(2)la gestion des investissements et des participations dans des sociétés-filles,l'exercice de fonctions d'administration,la fourniture de conseils,management et autres services de même nature que les activités de la société.Ces services peuvent être fournis sur une base contractuelle ou statutaire et en la qualité de conseiller externe ou d'organe;(3)l'octroi de prêt et avances sous quelle forme ou quelle durée que ce soit,à toutes les entreprises liées ou entreprises dans lesquelles elle possède une participation,leurs membres ou personnel,ainsi que garantir tous les engagements des mêmes entreprises
  3. La centralisation,la prestation et la coordination de toutes activités de services financiers,d'assurances,juridiques,administratives et commerciales
  4. La consultance,la formation et l'enseignement dans les domaines scientifiques et pharmaceutiques
deed of 29-11-2021 (in French)

Registered office and establishments

1 establishment
Establishment Since Unit number
Rue des Canadiens 24 registered office 7180 Seneffe 64210 Activities of holding companies 18-12-2014 2.237.633.315

Buildings and parcels at the address

Ground area
2,402 m²
Buildings
339 m²
Volume, LiDAR
1,897 m³
Tallest building
9.4 m
Buildings to scale, each on its own parcel
339 m², 9.4 m 339 m², 9.4 m

Location

registered office establishment The establishment unit on the map
13 companies at this address See who is registered here

Parcels

Cadastral parcelArea Buildings Height / floors
52063C0201/00F0072,402 m² 1 · 339 m² 9.4 m · 2

We would like to set cookies. That happens only with your consent. What we measure